BRCA1 and colorectal carcinoma: Taken together, these observations indicate that germline BRCA1 variants may, in a small proportion of variant carriers, play a driver role in CRC development or progression and that these patients might thus benefit from a treatment with poly (ADP-ribose) polymerase-inhibitors (PARPi).